CLLS - セレクティス (Cellectis S.A.) セレクティス

 CLLSのチャート


 CLLSの企業情報

symbol CLLS
会社名 Cellectis SA (セレクティス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS) used for gene excision correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field in pharmaceutical drug discovery programs in the agronomics bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States among others.   セレクティスは、フランスのゲノム工学会社。独自のコア技術を採用し、免疫腫瘍学の分野で製品を開発する。同社の製品には、B細胞悪性腫瘍などのCD19を有する細胞を標的とし殺傷することのできるT細胞製品のUCART19がある。また、製品の候補には、UCART123、UCARTCS1、UCART38などがある。   Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
本社所在地 8 rue de la Croix Jarry Paris 75013 FRA
代表者氏名 Andre Choulika アンドレ・チュリカ
代表者役職名 Chairman of the Board Chief Executive Officer Member of the Executive Board
電話番号 +33 1-8169-1600
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 135人
url www.cellectis.com
nasdaq_url https://www.nasdaq.com/symbol/clls
adr_tso 16101659
EBITDA EBITDA(百万ドル) -99.62027
終値(lastsale) 27.45
時価総額(marketcap) 441990539.55
時価総額 時価総額(百万ドル) 1121.578
売上高 売上高(百万ドル) 30.85860
企業価値(EV) 企業価値(EV)(百万ドル) 631.49400
当期純利益 当期純利益(百万ドル) -85.63750
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectis SA (ADR) revenues decreased 15% to $16.4M. Net loss decreased 30% to $32.4M. Revenues reflect Revenues decrease of 16% to $11.1M Other income decrease of 12% to $5.3M. Lower net loss reflects Financial expenses decrease of 74% to $3M (expense) Financial Income increase from $4.7M to $13M (income) Research and development expenses decrease of 5% to $36.4M (expense).

 CLLSのテクニカル分析


 CLLSのニュース

   Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT  2020/07/29 20:30:00 GlobeNewswire
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on…
   Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing  2020/07/21 20:30:00 GlobeNewswire
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on…
   Cellectis : Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies | MarketScreener  2020/06/25 20:39:04 MarketScreener
June 25, 2020 -New York -Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells , announced the publication of a new research… | June 25, 2020
   Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies  2020/06/25 20:30:00 GlobeNewswire
NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing…
   Moving Average Crossover Alert: Cellectis  2020/06/08 13:05:00 Zacks Investment Research
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT  2020/07/29 20:30:00 GlobeNewswire
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on…
   Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing  2020/07/21 20:30:00 GlobeNewswire
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on…
   Cellectis : Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies | MarketScreener  2020/06/25 20:39:04 MarketScreener
June 25, 2020 -New York -Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells , announced the publication of a new research… | June 25, 2020
   Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies  2020/06/25 20:30:00 GlobeNewswire
NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing…
   Moving Average Crossover Alert: Cellectis  2020/06/08 13:05:00 Zacks Investment Research
Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Cellectis : Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results | MarketScreener  2020/03/04 21:32:02 MarketScreener
Enrollment ongoing in Phase 1 dose-escalation trials AMELI-01 in r/r AML patients, BALLI-01 in r/r B-ALL patients and MELANI-01 in r/r MM patients Expanding collaboration with Servier on UCART19… | March 4, 2020
   Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products  2020/03/04 21:05:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products
   Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST  2020/02/25 21:30:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
   Cellectis : and Servier Expand Collaboration on UCART19 Products | MarketScreener  2020/02/18 21:31:02 MarketScreener
Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A … | February 18, 2020

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレクティス CLLS Cellectis S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)